Sanovas Commercializes Product Designed to Identify Poorly Cleaned Medical Devices

In the wake of recent headlines about infections related to inadequately reprocessed medical devices, Sanovas Inc., a life sciences company accelerating the development and commercialization of next-generation micro-invasive diagnostics, devices and drug delivery technologies, announces that its MicroCam Inc. subsidiary has commenced commercialization of the MicroCam™ System via its OEM partnership with Healthmark Industries, which has launched its new product, the Flexible Inspection Scope.

"Sophisticated modern surgical instruments, such as endoscopes, have revolutionized surgery, of course. But they are very difficult to clean," says Ralph Basile, vice president of marketing for Healthmark Industries. "The Sanovas MicroCam lets us inspect medical devices, such as endoscopes, with clarity of image that heretofore was not possible with affordable technology."

The MicroCam System represents an entirely new concept in medical imaging that has not been possible, until now. The MicroCam System is a highly integrated platform of proprietary micro optics, electronics and software. The plug-and-play capabilities of the 3mm-diameter, MicroCam System enable it to be sold as an OEM product as well as a branded MicroCam product, which MicroCam Inc. is pursuing simultaneously with its OEM strategy.

"MicroCam is paving the way for a paradigm shift in minimally invasive surgery toward multimodal imaging methods, linearly integrated medical devices, and natural orifice surgery," says Larry Gerrans, co-founder, president and CEO of Sanovas, and inventor of the MicroCam system. "MicroCam's small-diameter plug-and-play optics represent a highly disruptive leap in technology, cost, and portability. This is a unique platform solution whose time has come. The technology will, most certainly, evolve the interventional capabilities in the existing market and expand the growth of minimally invasive surgery to nearly 3.1 billion patients in the emerging markets."

Source: Sanovas Inc.